<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: SEPTEMBER 30, 1996
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period From __________ to __________.
Commission File Number: 0-27120
KENSEY NASH CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE 36-3316412
(State or other jurisdiction (IRS Employer Identification No.)
of incorporation or organization)
MARSH CREEK CORPORATE CENTER, 55 EAST UWCHLAN AVENUE, SUITE 204,
EXTON, PENNSYLVANIA 19341
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (610) 524-0188
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
--- ---
As of October 31, 1996, there were outstanding 7,165,900 shares of Common
Stock, par value $.001, of the registrant.
1
<PAGE> 2
KENSEY NASH CORPORATION
QUARTER ENDED SEPTEMBER 30, 1996
<TABLE>
<CAPTION>
INDEX
PAGE
----
<S> <C>
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Condensed Consolidated Balance Sheets
as of September 30, 1996 (Unaudited) and June 30, 1996 .............. 3
Condensed Consolidated Statements of Operations
for the three months ended September 30, 1996 and 1995 (Unaudited) ... 4
Condensed Consolidated Statements of Cash Flows
for the three months ended September 30, 1996 and 1995 (Unaudited) ... 5
Notes to Condensed Consolidated Financial Statements (Unaudited) ...... 6
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS ......................... 9
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K ............................................... 12
SIGNATURES .................................................................................. 13
</TABLE>
2
<PAGE> 3
ITEM 1. FINANCIAL STATEMENTS
PART I - FINANCIAL INFORMATION
KENSEY NASH CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
SEPTEMBER 30, JUNE 30,
1996 1996
(UNAUDITED)
------------ -----------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents................................................................ $4,772,271 $4,549,707
Short-term investments................................................................... 6,271,022 7,184,244
Trade receivables........................................................................ 814,340 914,502
Other receivables (including approximately $22,000 and $21,000 at September 30, 1996
and June 30, 1996, respectively, due from employees) (Notes 2 and 6).................... 1,478,936 1,017,811
Inventory................................................................................ 500,095 412,843
Prepaid expenses, accrued interest and other............................................. 170,414 259,906
------------ -----------
Total current assets.................................................................. 14,007,078 14,339,013
------------ -----------
Property, plant and equipment, at cost:
Leasehold improvements................................................................... 2,156,895 1,828,106
Machinery, furniture and equipment....................................................... 2,137,509 1,878,993
------------ -----------
Total................................................................................. 4,294,404 3,707,099
Accumulated depreciation................................................................. (1,487,688) (1,344,329)
------------ -----------
Total property, plant and equipment................................................... 2,806,716 2,362,770
------------ -----------
Other assets:
Restricted investments (Note 5).......................................................... 2,917,539 2,917,539
Leased property under capital leases, less accumulated amortization of $94,295 and
$102,692 at September 30, 1996 and June 30, 1996, respectively........................ 100,614 112,047
Noncompete agreement, less accumulated amortization of $93,352 and $88,351 at
September 30, 1996 and June 30, 1996, respectively.................................... 6,648 11,649
------------ -----------
Total other assets.................................................................... 3,024,801 3,041,235
------------ -----------
Total..................................................................................... $19,838,595 $19,743,018
============ ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable......................................................................... $559,017 $839,437
Accrued expenses......................................................................... 349,148 400,813
Line of credit (Note 4).................................................................. 6,523,337 6,356,824
Current portion of capital lease obligations............................................. 42,207 43,807
Deferred income.......................................................................... 20,000
------------ -----------
Total current liabilities............................................................. 7,473,709 7,660,881
------------ -----------
Obligations under capital leases.......................................................... 71,135 81,348
------------ -----------
Total liabilities..................................................................... 7,544,844 7,742,229
------------ -----------
Commitments and Contingencies (Note 5)
Stockholders' equity:
Preferred stock, $.001 par value, 100,000 shares authorized, no shares issued or
outstanding at September 30, 1996 and June 30, 1996...................................
Common stock, $.001 par value, 25,000,000 shares authorized, 7,164,750 and 7,156,493
shares issued and outstanding at September 30, 1996 and June 30, 1996, respectively... 7,164 7,156
Capital in excess of par value............................................................ 33,887,457 33,815,216
Accumulated deficit....................................................................... (21,600,870) (21,821,583)
------------ -----------
Total stockholders' equity............................................................ 12,293,751 12,000,789
------------ -----------
Total..................................................................................... $19,838,595 $19,743,018
============ ===========
</TABLE>
See notes to condensed consolidated financial statements.
3
<PAGE> 4
KENSEY NASH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30,
--------------------------
1996 1995
----------- -----------
<S> <C> <C>
Revenues:
Net sales......................................... $603,746 $402,949
Research and development.......................... 619,363 330,111
Milestone fees.................................... 1,050,000
Royalty income.................................... 55,000 33,431
----------- -----------
Total revenues................................... 2,328,109 766,491
----------- -----------
Operating costs and expenses:
Cost of products sold............................. 558,440 474,175
Research and development.......................... 1,084,292 912,928
Selling, general and administrative............... 471,727 650,866
Deferred compensation, officers and directors..... 594,959
----------- -----------
Total operating costs and expenses............... 2,114,459 2,632,928
----------- -----------
Income (loss) from operations...................... 213,650 (1,866,437)
----------- -----------
Other income (expense):
Interest expense.................................. (171,752) (331,029)
Interest income................................... 178,157 1,861
Other............................................. 658 21,560
----------- -----------
Total other income (expense)--net................ 7,063 (307,608)
----------- -----------
Net income (loss).................................. $220,713 $(2,174,045)
=========== ===========
Earnings (loss) per common share................... $0.03 $(0.49)
=========== ===========
Weighted average common shares outstanding......... 7,389,318 4,446,437
=========== ===========
</TABLE>
See notes to condensed consolidated financial statements.
4
<PAGE> 5
KENSEY NASH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30,
------------------------------
1996 1995
----------- ------------
<S> <C> <C>
Operating activities:
Net income (loss)............................................... $ 220,713 $ (2,174,045)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization................................. 159,793 99,651
Deferred revenue earned....................................... (50,000)
Deferred compensation......................................... 892,970
Interest expense not requiring cash........................... 166,513 327,877
Changes in assets and liabilities which (used) provided cash:
Accounts receivable........................................... (360,963) (381,480)
Prepaid expenses, accrued interest and other current assets... 89,492 (292,644)
Inventory..................................................... (87,252) 34,443
Accounts payable and accrued expenses......................... (332,085) 775,878
----------- ------------
Net cash used in operating activities............................ (143,789) (767,350)
----------- ------------
Investing activities:
Sale of investments............................................. 913,222
Additions to property, plant and equipment...................... (587,305)
----------- ------------
Net cash provided by investing activities........................ 325,917
----------- ------------
Financing activities:
Principal payments under capital leases......................... (11,813) (14,025)
Proceeds from long-term debt.................................... 5,930
Repayments of long-term debt.................................... (658)
Proceeds from notes payable and line of credit.................. 530,000
Net advances borrowings and repayments.......................... (20,000) 239,484
Proceeds from issuance of common stock.......................... 72,249
----------- ------------
Net cash provided by financing activities........................ 40,436 760,731
----------- ------------
Increase (decrease) in cash and cash equivalents................. 222,564 (6,619)
Cash and cash equivalents, beginning of period................... 4,549,707 7,866
----------- ------------
Cash and cash equivalents, end of period......................... $ 4,772,271 $ 1,247
=========== ============
Supplemental disclosure of cash flow information:
Cash paid during the period for interest........................ $ 5,239 $ 0
=========== ============
</TABLE>
See notes to condensed consolidated financial statements.
5
<PAGE> 6
KENSEY NASH CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1--CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
BASIS OF PRESENTATION
The condensed consolidated balance sheet at June 30, 1996 has been
condensed from the audited balance sheet at that date. The condensed
consolidated balance sheet at September 30, 1996, the condensed
consolidated statements of operations for the three months ended
September 30, 1996 and 1995 and the condensed consolidated statements of
cash flows for the three months ended September 30, 1996 and 1995 have
been prepared by Kensey Nash Corporation (the "Company") and have not
been audited by the Company's Independent Auditors. In the opinion of
management, all adjustments (which include only normal recurring
adjustments and the adjustment described in Note 6) necessary to present
fairly the financial position, results of operations and cash flows at
September 30, 1996 and for all periods presented have been made.
Certain information and note disclosures normally included in the
Company's annual financial statements prepared in accordance with
generally accepted accounting principles have been condensed or omitted.
These condensed consolidated financial statements should be read in
conjunction with the financial statements and notes thereto included in
the Company's June 30, 1996 consolidated financial statements filed with
the Securities and Exchange Commission on Form 10-K. The results of
operations for the period ended September 30, 1996 are not necessarily
indicative of operating results for the full year.
NET INCOME (LOSS) PER SHARE
For the three months ended September 30, 1996, net income per share is
computed using the weighted average number of shares of common stock
outstanding. Common equivalant shares from options are included in the
computation (using the treasury stock method) when their effect is
dilutive. For the three months ended September 30, 1995 the weighted
average common shares outstanding have been increased by 446,437 shares
which is the number of Common Stock equivalents issued within one year of
the Company's public offering, with exercise or issue prices below the
initial public offering price.
STATEMENT OF CASH FLOWS
For purposes of reporting cash flows, all highly liquid investments with
original maturities of three months or less are considered cash
equivalents.
INVESTMENTS
Investments at September 30, 1996 and June 30, 1996 consist of short-term
Certificates of Deposit and U.S. Treasury Bills. Such investments have
been classified as available for sale securities except for those pledged
as collateral which are included in restricted investments (see Note 5).
As of September 30, 1996 and June 30, 1996, the fair market value of all
investments approximates original cost.
NEW ACCOUNTING PRONOUNCEMENTS
Effective July 1, 1996, the Company formally adopted Statement of
Financial Accounting Standards ("SFAS") No. 121. "Accounting for the
Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed
Of". This statement requires that long-lived assets be reviewed for
impairment whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable. The resultant
impairment, if any, is measured based on the fair value of the asset.
The adoption of SFAS No. 121 did not have a material impact on the
Company.
6
<PAGE> 7
Effective July 1, 1996, the Company formally adopted SFAS No. 123,
"Accounting for Stock-based Compensation Plans." The Company will adopt
this statement by disclosing the proforma net income and net earnings
per share amounts assuming the fair value method in the fiscal year end
1997 financial statements, as required. As a result, the adoption of
this statement will not have any impact on reported results of
operations and financial position.
NOTE 2--ANGIO-SEAL PRE-MARKET APPROVAL
On September 30, 1996, the Company received pre-market approval for the 8
French ("F") size Angio-Seal device (the "Angio-Seal") from the Food and
Drug Administration (the "FDA"). Under the Company's licensing agreement
(the "Licensing Agreement") with American Home Products ("AHP"), a
milestone fee of $1,050,000 was earned upon receipt of FDA approval and
has been recorded as a component of other receivables at September 30,
1996. Also under the Licensing Agreement, the Company has available a
$3,000,000 advance on future royalties. No portion of such advance has
been taken at September 30, 1996.
NOTE 3--INVENTORY
Inventory primarily includes the cost of material utilized in the
processing of the Company's products. Inventory is as follows:
<TABLE>
<CAPTION>
SEPTEMBER 30, 1996 JUNE 30, 1996
------------------ -------------
<S> <C> <C>
Raw Materials $418,600 $394,043
Work in Process $81,495 18,800
------------------ -------------
Total $500,095 $412,843
================== =============
</TABLE>
NOTE 4 -- LINE OF CREDIT
At September 30, 1996 and June 30, 1996, the amount available under
the Company's credit agreement with AHP (the "Credit Agreement") was
$5,000,000. Debt outstanding under the Credit Agreement includes accrued
interest of $1,523,337 and $1,356,824 at September 30, 1996 and June 30,
1996, respectively. Interest accrues at a rate of prime plus 2% (10.25%
at September 30, 1996 and June 30, 1996) and is payable at maturity.
Under the terms of the Credit Agreement, the Company may not pay any cash
dividends. Patent rights for the Angio-Seal are pledged as collateral.
Loans made under this facility matured at the earlier of receipt of
pre-market approval for the Angio-Seal from the FDA or December 31, 1996,
and were therefore classified as a current obligation at September 30,
1996 and June 30, 1996. Under the terms of the Credit Agreement, AHP may
offset fiscal 1997 milestones and advances against amounts due under the
Credit Agreement at September 30, 1996 and June 30, 1996.
NOTE 5 -- COMMITMENTS AND CONTINGENCIES
The Company entered into an agreement whereby the Company pledged
$2,917,539 in investments as collateral to secure certain bank loans to
employees which were used by such employees for the payment of taxes
incurred by such employees as the result of the receipt of Common Stock
in settlement of the Employee Stock Rights. In exchange for the Company
pledging collateral for such loans, each affected employee has pledged
their Common Stock as collateral to the Company. The balance outstanding
on such employee loans was $2,071,942 at September 30, 1996.
7
<PAGE> 8
NOTE 6--MAJOR DAMAGE TO FACILITY
On January 8, 1996, the Company's facility sustained significant damage
from a roof collapse resulting from a major snowstorm. The production
of the Company's products was halted until the destroyed facilities could
be reconstructed. Construction was completed in late March 1996 and
production resumed at such time. The Company maintains insurance for
both property damage and business interruption. The policy providing
the coverage is subject to a $1,000 deductible.
Under the property damage portion of the policy, the Company recovered
$1,186,619 as final settlement for property damage in fiscal year 1996.
Of this amount, $500,000 was received during fiscal year 1996 and the
remaining $686,619 recorded as a component of other receivables at
June 30, 1996 and received in July 1996.
Under the business interruption portion of the policy, the Company
incurred continuing fixed expenses during the reconstruction period which
are covered expenses under the policy. As such, the Company has recorded
$287,742 in continuing fixed payroll costs and related benefits as a
component of other receivables at September 30, 1996 and June 30, 1996.
The related cost of products sold, selling general and administrative
expense and research and development expense was offset in the
consolidated statements of operations at June 30, 1996. Any amounts
received in excess of continuing fixed expenses will be recorded as
income when the related claim is settled.
The Company continues to pursue additional recoveries under its business
interruption policies related to the damage of the facility. The claim
under such policy was filed with the carrier in September 1996.
8
<PAGE> 9
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
OVERVIEW
The Company designs, develops and manufactures a proprietary line of
absorbable medical devices for the sealing of arterial punctures created during
diagnostic and therapeutic cardiovascular procedures such as angiography,
angioplasty, atherectomy and the placement of stents. The Company's
proprietary principal product, the Angio-Seal, has been designed to provide a
safe, effective and rapid method of sealing arterial punctures. The Company's
goal is to replace the current standard of care, manual compression, with the
Angio-Seal by introducing a device which allows for faster treatment, reduced
procedure cost and increased patient comfort. The time required for manual
pressure generally ranges from 10 to 30 minutes and in some instances several
hours. The Angio-Seal is designed to take a trained physician less than two
minutes to place and eliminate the need for manual pressure following the
procedure. The Company is developing other sizes of the Angio-Seal, including
6F and 10F sizes (together with Angio-Seal, the "Angio-Seal Product Line"), to
address broader market applications. In addition to the Angio-Seal Product
Line, the Company manufactures its proprietary collagen for use by third
parties, and is developing additional products related to its puncture closure
technology, including the Laparo-Seal, a device for closing punctures from
laparoscopic surgery, and a rotary catheter for application in opening occluded
bypass grafts.
The Company has a strategic relationship with AHP whereby AHP will
manufacture and market the Angio-Seal Product Line worldwide. The 8F
Angio-Seal was approved for sale in Europe (CE Mark) in September 1995 and in
the United States in September 1996. The Angio-Seal is also approved for sale
in Canada.
THREE MONTHS ENDED SEPTEMBER 30, 1996 COMPARED TO THREE MONTHS ENDED
SEPTEMBER 30, 1995
Revenues for these periods consisted of net sales, research and
development revenue, milestone fees and royalty income. Revenues increased
204% to $2,328,000 in the three months ended September 30, 1996 from $766,000
in the three months ended September 30, 1995. Net sales of products increased
50% to $604,000 from $403,000 for the three months ended September 30, 1996 and
1995, respectively. Research and development revenues increased 88% to
$619,000 from $330,000 for the three months ended September 30, 1996 and 1995,
respectively. The increase in net sales was mainly attributable to the
increased demand for the Angio-Seal in Europe, increased clinical device
requirements and increased sales of biomaterials to customers other than AHP.
The increase in research and development revenues relates to increased activity
in contract research and development from AHP for the clinical trial program
and for additional sizes of and product enhancements to the Angio-Seal Product
Line. The $1.05 million milestone fee in the three months ended September 30,
1996 represents the final milestone under the License Agreement with AHP which
was earned by the Company upon receipt of FDA pre-market approval. Royalty
income increased 65% to $55,000 from $33,000 in the three months ended
September 30, 1996 and 1995, respectively. This increase reflects a greater
number of units sold in the European market versus the same quarter a year
earlier. As the Company and AHP increase production and continue to introduce
the Angio-Seal in Europe and in the United States, the Company expects royalty
income to become a significant source of revenue. Royalty rates are based on
volume of units sold and are comparable in both the domestic and foreign
licensing agreements with AHP.
Cost of products sold increased 18% to $558,000 in the three months ended
September 30, 1996 from $474,000 in the three months ended September 30, 1995.
This increase reflects greater net sales of products offset by manufacturing
efficiencies realized as production levels rise.
9
<PAGE> 10
Research and development expense, including regulatory and clinical
expense, increased 19% to $1,084,000 in the three months ended September 30,
1996 from $913,000 in the three months ended September 30, 1995. This increase
was primarily due to an increase in personnel costs and outside expenses in
conjunction with the development of the Angio-Seal Product Line, Laparo-Seal
and rotary technology. The Company expects research and development expense to
continue at recent levels as it develops additional sizes of the Angio-Seal,
investigates and develops new products, conducts clinical trials, seeks
regulatory approval for its products and implements manufacturing improvements
related to the collagen business.
Selling, general and administrative expense decreased 28% to $472,000 in
the three months ended September 30, 1996 from $651,000 in the three months
ended September 30, 1995. This decrease was primarily due to the recording of
deferred compensation for employees other than officers and directors of
$298,000 in the quarter ended September 30, 1995. Since the Company's initial
public offering (the "IPO") in December 1995, no deferred compensation expense
has been incurred.
Deferred compensation expense, officers and directors, of $595,000 in the
three months ended September 30, 1995 resulted from the recording of deferred
compensation prior to the IPO.
Interest expense decreased 48% to $172,000 in the three months ended
September 30, 1996 from $331,000 in the three months ended September 30, 1995.
This decrease was due to the repayment of certain investor notes with the
proceeds of the IPO in December 1995. Interest expense for the quarter ended
September 30, 1996 relates to the Credit Agreement. Interest income increased
to $178,000 in the three months ended September 30, 1996 from $2,000 in the
three months ended September 30, 1995. The three months ended September 30,
1996 reflects interest earned on the cash equivalents and investments purchased
with the proceeds of the IPO.
LIQUIDITY AND CAPITAL RESOURCES
The Company has financed its operations since inception through the sale
of equity securities, licensing of technology, research and development
arrangements, debt and product sales. On December 13, 1995, the Company
completed the IPO, issuing 2.7 million shares of Common Stock at $12.00 per
share, resulting in approximately $29.1 million in net proceeds to the Company.
The proceeds have been and are being used primarily for research and
development, including clinical trials; expansion of the Company's
manufacturing capabilities; repayment of certain indebtedness; and working
capital and general corporate purposes.
Net cash used in the Company's operating activities during the three
months ended September 30, 1996 and 1995 was $144,000 and $767,000,
respectively. The decrease in net cash used in operating activities was
primarily due to net income of $221,000 for the period ended September 30,
1996 compared to a net loss of $2,200,000 for the period ending September 30,
1995. The net loss for the period ended September 30, 1995 was significantly
offset by non-cash adjustments for deferred compensation and interest expense.
Changes in asset and liability balances for the three months ended September
30, 1996 resulted in a $691,000 use of cash in operating activities offset by
$326,000 of non-cash adjustments for depreciation and interest expense.
Capital expenditures were $587,000 for the three months ended September
30, 1996, $434,000 of which related to reconstruction and expansion of the
Company's facility. The remaining capital expenditures related to the
expansion of the Company's manufacturing capabilities.
The Company's cash, cash equivalents and short-term investments were
$11,043,000 at September 30, 1996. In addition, the Company has pledged
$2,918,000 in investments (not included in the $11,043,000) as collateral to
secure bank loans made to employees for the payment of taxes incurred by such
employees as a result of their receipt of Common Stock in settlement of the
Employee Stock
10
<PAGE> 11
Rights at the time of the IPO. In exchange for the Company's pledging this
collateral, the employees have pledged their Common Stock as collateral to
the Company.
The Company had $6,523,000 of debt and accrued interest outstanding under
the AHP Credit Agreement as of September 30, 1996. Interest accrued at the
prime rate of interest plus 2% (10.25% at September 30, 1996). The debt
matured upon FDA pre-market approval of the Angio-Seal which was received on
September 30, 1996. The FDA approval required AHP to pay the Company a total
of $4,050,000 (a $1,050,000 milestone fee earned upon approval and a $3,000,000
royalty advance). In October 1996, the Company used the milestone fee, royalty
advance and cash on hand to repay the Credit Agreement balance.
The Company anticipates that its results of operations will fluctuate for
the foreseeable future due to a number of factors. Such factors include AHP's
performance in the marketing, manufacturing and distribution of the Angio-Seal
Product Line, the timing of future regulatory approvals in the United States
and in countries outside of Europe including Japan and Australia, the results
of ongoing and planned clinical trials for the Angio-Seal and other products,
the acceptance of the Company's products in the marketplace and competitive
products generally and in particular those designed for the sealing of arterial
site punctures.
The Company plans to continue to expend substantial resources in funding
clinical trials to gain regulatory approvals, make additional marketing claims
and continue to expand research and development activities for the Angio-Seal,
Laparo-Seal, rotary technology and biomaterials products.
The Company believes the initial public offering proceeds combined with
cash generated from operations will be sufficient to meet the Company's
operating and capital requirements for at least the next twelve months.
Within the Company's Proxy Statement, filed with the SEC on October 30,
1996, the Summary Compensation Table erroneously presented bonuses earned
during the fiscal year ended June 30, 1995 by each of the Company's four
officers as bonuses earned during the fiscal year ended June 30, 1996. There
were no bonuses earned by such officers for fiscal 1996. All bonuses presented
on the fiscal 1996 line within the Summary Compensation Table should
appropriately be presented on the fiscal 1995 line, consistent with the
Company's Prospectus, filed with the SEC on December 13, 1995. This topic was
also discussed in the Report of the Compensation Committee of the Board of
Directors. All bonuses discussed in such report as earned in fiscal 1996 should
appropriately read as earned in fiscal 1995.
Statements contained in this Form 10-Q that are not historical facts are
forward-looking statements that are made pursuant to the Safe Harbor provisions
of the Private Securities Litigation Reform Act of 1995. The Company cautions
that a number of important factors could cause the Company's actual results for
1997 and beyond to differ materially from those in any forward-looking
statements made by, or on behalf of, the Company. These important factors
include, without limitation, the time, effort and priority level that AHP
attaches to the Angio-Seal and AHP's ability to successfully market and
manufacture the Angio-Seal, the Company's ability to manufacture Angio-Seal
components, timing of future FDA approvals, announcements of technological
innovations or the introduction of new products by the Company or its
competitors, competition by rival developers of puncture closure devices,
general business conditions in the healthcare industry and general economic
conditions. Results of operations in any past period should not be considered
indicative of the results to be expected for future periods. Fluctuations in
operating results may also result in fluctuations in the price of the Common
Stock.
11
<PAGE> 12
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
A. Exhibits.
None
B. Reports on Form 8-K.
None
C. Financial Data Schedule
12
<PAGE> 13
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KENSEY NASH CORPORATION
Date: November 14, 1996 By: /s/ Joseph W. Kaufmann
--------------------------------------
Joseph W. Kaufmann
President, Chief Executive Officer and
Chief Financial Officer
13
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> JUN-30-1997
<PERIOD-START> JUL-01-1996
<PERIOD-END> SEP-30-1996
<CASH> 4,772,271
<SECURITIES> 6,271,022
<RECEIVABLES> 2,293,276
<ALLOWANCES> 0
<INVENTORY> 500,095
<CURRENT-ASSETS> 14,007,078
<PP&E> 4,294,404
<DEPRECIATION> 1,487,688
<TOTAL-ASSETS> 19,838,595
<CURRENT-LIABILITIES> 7,473,709
<BONDS> 0
<COMMON> 7,164
0
0
<OTHER-SE> 12,286,587
<TOTAL-LIABILITY-AND-EQUITY> 19,838,595
<SALES> 603,746
<TOTAL-REVENUES> 2,328,109
<CGS> 558,440
<TOTAL-COSTS> 2,114,459
<OTHER-EXPENSES> 658
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 171,752
<INCOME-PRETAX> 220,713
<INCOME-TAX> 0
<INCOME-CONTINUING> 220,713
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 220,713
<EPS-PRIMARY> 0.03
<EPS-DILUTED> 0
</TABLE>
